secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bio Green Med Solution, Inc. (BGMS)
CIK:        0001130166
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0001104659-23-059117
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cyclacel Q1 net loss $5.8M; non-dilutive $4.7M tax credit bolsters cash into Q1 2024
--------------------------------------------------------------------------------

- Net loss $5.8M in Q1 2023 vs $4.1M year ago; cash $11.4M plus $4.7M R&D tax credit received.
- R&D expenses $5.7M, up 14% YoY, with fadraciclib costs $4.1M and plogosertib $1.4M.
- Expects Phase 1/2 data for oral fadraciclib and plogosertib in 2023; Phase 2 PoC enrollment ready.
- Cash runway estimated into Q1 2024; royalty income declined $1.1M YoY.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1130166/000110465923059117/0001104659-23-059117-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1130166/000110465923059117/tm2315482d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-059117

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer